Dulaglutide vs Selank
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideCognitive Enhancement
Selank- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
- Half-Life
- ~5 days
- Minutes (but effects persist for hours)
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 250–500 mcg
- Frequency
- Once weekly
- 1–3 times daily
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Reduces anxiety without sedation
- Enhances memory and learning
- Improves focus and concentration
- Stabilizes mood
- Reduces physiological stress response
- May enhance motivation
- No addiction potential or withdrawal
- Fast-acting — effects within 20–30 minutes
- Approved clinically in Russia for anxiety disorders
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Mild sedation at higher doses (paradoxical)
- Fatigue (rare)
- Irritability during discontinuation (uncommon)
- Stacks With
- —
- —